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Abstract: Recently, solid lipid nanoparticles (SLNs) have attracted increasing attention owing to their
potential as an oral delivery system, promoting intestinal absorption in the lymphatic circulation
which plays a role in disseminating metastatic cancer cells and infectious agents throughout the
body. SLN features can be exploited for the oral delivery of theranostics. Therefore, the aim of this
work was to design and characterise self-assembled lipid nanoparticles (SALNs) to encapsulate and
stabilise iron oxide nanoparticles non-covalently coated with heparin (Fe@hepa) as a model of a
theranostic tool. SALNs were characterised for physico-chemical properties (particle size, surface
charge, encapsulation efficiency, in vitro stability, and heparin leakage), as well as in vitro cytotoxicity
by methyl thiazole tetrazolium (MTT) assay and cell internalisation in CaCo-2, a cell line model used
as an indirect indication of intestinal lymphatic absorption. SALNs of about 180 nm, which are stable
in suspension and have a high encapsulation efficiency (>90%) were obtained. SALNs were able to
stabilise the heparin coating of Fe@hepa, which are typically unstable in physiological environments.
Moreover, SALNs–Fe@hepa showed no cytotoxicity, although their ability to be internalised into
CaCo-2 cells was highlighted by confocal microscopy analysis. Therefore, the results indicated that
SALNs can be considered as a promising tool to orally deliver theranostic Fe@hepa into the lymphatic
circulation, although further in vivo studies are needed to comprehend further potential applications.
Keywords: theranostics; solid lipid nanoparticles; iron oxide nanoparticles; heparin coating; intestinal
lymphatic absorption
1. Introduction
Currently, oral delivery is the most accepted route of drug administration, even though it is
associated with poor drug bioavailability. One of the most promising strategies to overcome these
limitations is the use of nanomedicine or nano-drug delivery systems [1]. As an example, solid
lipid nanoparticles (SLNs) have attracted increasing attention owing to their biocompatibility and
biodegradability. SLNs are composed of lipids in a solid state at room temperature and surfactants.
They are produced using hot or cold homogenisation without the employment of organic solvents and
generally have low production costs. SLNs offer advantages such as good tolerability, high oral drug
Molecules 2017, 22, 963; doi:10.3390/molecules22060963 www.mdpi.com/journal/molecules
Molecules 2017, 22, 963 2 of 17
bioavailability and low acute and chronic toxicity [2,3]. Moreover, being composed of lipids, SLNs
have shown good potential in achieving drug delivery into the systemic circulation through intestinal
lymphatic absorption [4–6]. After oral administration, small and hydrophilic substances enter in the
systemic circulation by a passive absorption mechanism through enterocytes. On the contrary, large
and lipophilic compounds with a logP ≥ 5 (where P is the octanol/water partition coefficient), such as
components of SLNs, are metabolically stable (in the intestinal lumen and within enterocytes) and can
be considered good candidates for lymphatic transport to the systemic circulation [7]. Drug adsorption
via the intestinal lymphatic system has several major advantages, including circumventing first-pass
metabolism and targeting drugs to diseases that spread through the lymphatic system. For example,
cancer cells use the lymph nodes as a reservoir to spread to the other areas of the body [8].
The main ways to deliver drugs to intestinal lymphatic vessels are through lymphatic capillaries,
gut-associated lymphoid follicles that form Peyer’s patch, and finally the intestinal walls via
transcellular absorption. This last route is the lymphatic target of lipid-based nanoformulations
because during transit across the enterocyte the lipids become associated with chylomicrons which are
secreted into the mesenteric lymph duct [9–12].
SLNs have to satisfy certain requirements to achieve lymphatic delivery. It was observed
that the uptake and fate of SLNs are influenced by particle size, surface hydrophobicity, type of
lipids, and concentration of the emulsifier [1,6,13]. Also, the surface charge plays an important role:
negatively-charged carriers have been reported to show higher lymphatic uptake than neutral or
positively-charged particles [1,9,14]. SLNs promote lymphatic absorption and can also be exploited for
theranostic purposes, which to the best of our knowledge, have not been extensively investigated [15].
Theranostics is the fusion of therapeutic and diagnostic approaches aiming to personalise and
advance medicine. Magnetic nanoparticles (MNPs) represent a particularly appropriate tool based
on their ability to be simultaneously functionalised and guided by external magnetic fields [16].
Some MNPs-based therapeutic applications include magnetic fluid hyperthermia (MFH), magnetic
resonance imaging (MRI) and magnetic drug targeting [17,18]. In this field, iron oxide (Fe3O4) MNPs
provide a unique nanoplatform with tunable sizes and surface chemistry studied extensively for
MRI and MFH applications [19]. Without a coating, MNPs have hydrophobic surfaces with a high
area to volume ratio and a propensity to agglomerate. An appropriate surface coating allows MNPs
to be and remain homogenously dispersed for longer times. Several materials have been used to
modify the surface of MNPs, such as organic polymers (dextran, chitosan, polyethylene glycol),
organic surfactants (sodium oleate and dodecylamine), and metals [16]. Vismara et al. proposed
the use of heparin as a non-covalent coating for iron oxide nanoparticles (Fe@hepa) [20]. Heparin,
a natural polysaccharide with many bioactive properties, is a heterogeneous, polydispersed, highly
sulphated glycosaminoglycan composed of 1 → 4 linked disaccharide repeating units. Each unit
consists of an α-D-glucosamine and either a hexuronic acid, α-L-idruronic or β-D-glucoronicacid unit,
with O-sulphate groups at different positions of the disaccharide. Various studies have demonstrated
that heparin and low-molecular-weight heparins, in addition to having anticoagulant properties, are
anti-angiogenic agents and can be used as vectors to reach tumour sites due to their ability to bind
over-expressed proteins [21–23]. Thanks to these features, the heparin coating specifically directs iron
oxide nanoparticles to tumour environments in order to accomplish the theranostic aim. Moreover,
Vismara et al. demonstrated an increased stability in a water suspension of Fe@hepa nanoparticles with
respect to naked iron oxide by conferring a negative charge due to the heparin coating [20]. However,
the heparin surface shell is instable in physiologic environment where the presence of ions reduces the
strength of the electrostatic bond between the positive iron oxide core and the negative heparin chain.
Therefore, the purpose of the present work was to design a nano-theranostic tool based on
Fe@hepa nanoparticles for oral absorption through the lymphatic route. To the best of our knowledge,
in the theranostic field poor attention has been addressed to the study of this promising approach. In
order to stabilise the heparin coating in physiological environments, and at the same time promote oral
absorption through the lymphatic route, Fe@hepa were encapsulated in a biocompatible solid lipid
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shell to obtain self-assembled lipid nanoparticles (SALNs). SALNs were obtained by self-emulsification
process and were characterised with regard to their size, encapsulation efficiency, in vitro cytotoxicity
and ability to be internalised into the CaCo-2 cell line (colon rectal adenocarcinoma cell line of human
origin) used as a model for an indirect indication of lymphatic uptake.
2. Results
2.1. SALN Characterisation
By using the original self-emulsification process, two SALNs–Fe@hepa samples were developed
using 1 or 5 mg of Fe@hepa (namely SALNs–Fe@hepa1 and SALNs–Fe@hepa5, respectively).
The particle size, polydispersity index (PDI) and Z-potential values obtained with photon correlation
spectroscopy (PCS) analysis are shown in Table 1. No differences in the particle size nor in the PDI
values were observed, regardless of the amount of Fe@hepa used (all the samples were roughly of
180 nm with a PDI of 0.3), while the negative charge of the particle surface (Z-potential value) increased
with the increase of the initial amount of Fe@hepa utilised in the preparation. The particle size was
monitored for one month and no significant changes were observed (data not shown). The size and the
Z-potential of naked Fe@hepa were previously reported [20] and were 92 nm and −61 mV, respectively.
Table 1. Size, polydispersity index (PDI) and Z-potential values of loaded and unloaded self-assembled
lipid nanoparticles (SALNs). Fe@hepa1: iron oxide nanoparticles non-covalently coated with heparin
(1 mg); Fe@hepa5: iron oxide nanoparticles non-covalently coated with heparin (5 mg).
Sample Size (nm) PDI Z-Potential (mV)
Unloaded SALNs 182 ± 15 0.295 ± 0.015 −16.4 ± 4.7
SALNs–Fe@hepa1 183 ± 18 0.278 ± 0.008 −15.5 ± 5.8
SALNs–Fe@hepa5 186 ± 21 0.364 ± 0.013 −24.0 ± 5.5
2.2. Morphological Studies
Morphological characterisation of the samples was performed using the scanning electron
microscopy analysis (SEM modality) to visualise the particles in solid form, while the scanning
transmission electron microscopy analysis (STEM modality) was used to observe the samples as
suspension. Both the analyses were performed in high-vacuum conditions. Figure 1A shows, as an
example, the image of SALNs–Fe@hepa1 at high magnification (100,000×) using the SEM technique.
Even if SALNs appear aggregated in clusters, each single particle can be clearly recognised as a distinct
solid structure with a roughly spherical morphology.
By STEM modality (Figure 1B), unloaded SALNs in suspension are hardly detectable due to their
intrinsically low electron density that limits the resolution. However, even if the particles appear as
weak-contrast dark formations, their imperfectly spherical morphology is easily observable.
Figure 1C,D shows the STEM images of loaded particles (SALNs–Fe@hepa5). At low
magnification (Figure 1C), SALNs–Fe@hepa5 appear irregular in the shape, as observed also for
the unloaded particles, but with a darker inner structure. The high-contrast dark part in the core region
of each particle can be assigned to the Fe@hepa clusters, while the clear part surrounding the core
regions can be attributable to the lipid shell. At high magnification (Figure 1D) one single particle
with a rough contour is observed. Within the particle, even if not perfectly in the centre, dark small
dots, due to clusters of Fe@hepa nanoparticles, are clearly visible. The clusters appear surrounded by
a weak-contrast dark part attributable to the lipid matrix, according to the images of the unloaded
sample (Figure 1B). The particle sizes of SALNs–Fe@hepa5 as well as of the Fe@hepa nanoparticles are
also consistent with PCS analysis results reported in Table 1 and in previous studies [20], respectively.
To confirm the composition of the particles observed by the electron microscopy analysis, the
qualitative energy dispersive X-ray (EDX) analysis was performed by the single-point method. A single
loaded nanoparticle, as observed in the image reported in Figure 1D, was analysed in comparison with
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an individual unloaded nanoparticle and the qualitative composition was reported in the EDX spectra
representing the plots of X-ray counts vs. elements. In spectrum relating to SALNs–Fe@hepa, the peak
of iron is clearly visible (Figure 2A), while it is absent in unloaded particles (Figure 2B), confirming the
presence of Fe@hepa into the loaded SALNs. In the spectra, the presence of Al and Si are probably due
to the support used for the analyses.Molecules 2017, 22, 963 4 of 17 
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2.3. Drug Loading and Encapsulation Efficiency
The amount of Fe@hepa loaded inside SALNs was calculated by indirect method, i.e., analysing
the non-encapsulated amount of Fe@hepa. No significant differences are observed in the encapsulation
efficiency (EE%) between the samples (p > 0.05), while the drug loading (DL) increases five-fold in
SALNs-Fe@hepa5 (p < 0.001) (Table 2).
Table 2. Encapsulation efficiency (EE%) and drug loading (DL) of SALNs–Fe@hepa.
Sample EE% DL (µg Fe@hepa/mg SALNs-Fe@hepa)
SALNs–Fe@hepa1 86.6 ± 2.76 5.14 ± 0.01
SALNs–Fe@hepa5 91.5 ± 3.09 26.38 ± 0.70
2.4. In Vitro SALNs-Fe@hepa Stability
In order to verify the retention of Fe@hepa in SALNs stored as suspension at 4 ◦C, the spontaneous
Fe@hepa sedimentation from SALNs–Fe@hepa was monitored for both the samples for one month
after the preparation (t0). At predetermined time interval, the amount of Fe@hepa separated from
the suspension was measured by spectrophotometric method. These data were subtracted from the
initial Fe@hepa loading and the results are reported in the graph (Figure 3). The data indicate that
SALNs–Fe@hepa5 are more stable compared to the SALNs–Fe@hepa1. Indeed, for this sample, after
4 days, the loss of the cargo was only 4% compared to the initial content, indicating a good stability
of the system. Then, a very slow sedimentation rate of free Fe@hepa is observed in the remaining
time until a total loss of 6%. On the contrary, SALNs–Fe@hepa1 appeared quite instable in suspension,
showing a fast initial loss of cargo corresponding to about 11% in 4 days followed by a slower phase
of Fe@hepa release up to a total loss of 20% in one month. Therefore, given the weak stability in
suspension of SALNs–Fe@hepa1, this sample was not taken into account in the further experiments.
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2.5. Stabilisation of eparin oating
I or er to eval ate if t e e ca s latio of t e Fe e a i to S s as able to stabilise t e
he arin coating, the leakage of heparin form both naked Fe@hepa and SALNs-Fe@hepa5 was measured
in physiologic solution (NaCl 0.9%). Indeed, the heparin shell is stable in water [20] but in the presence
of saline medium the interaction between heparin and iron oxide became weaker, resulting in the
release of heparin and in the loss of stability of the colloidal suspension [24]. Therefore, to measure
t e stability of the coating, experimental conditions with minimal perturbation (saline solution) were
considered and the amount of hepari released after only 1 h at room temperature was evaluated.
As reported in Table 3, in the case of naked Fe@hepa, as expected, a leakage of about 70% of the initial
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amount of heparin occurred while in the case of the SALNs–Fe@hepa5 no release of heparin in solution
was observed in the time period considered.
Table 3. Evaluation of the amount of heparin released in saline solution from SALNs–Fe@hepa5 and
naked Fe@hepa.
Sample Mass of Fe@hepa(µg)
Initial Amount of Heparin
in Fe@hepa (µg)
% of Heparin Released
in NaCl 0.9%
SALNs–Fe@hepa5 810 72.9 0
Fe@hepa 620 55.8 72
2.6. Cytotoxicity Assay
In order to determine the in vitro cytotoxicity of SALNs–Fe@hepa5 compared to naked Fe@hepa
and unloaded SALNs, the methyl thiazole tetrazolium test (MTT) was performed on the intestinal
CaCo-2 cell line after different incubation times (2, 4, and 6 h). For each time, various concentrations of
SALNs (0.8, 1.2, 1.6, 2 mg/mL) and the respective amount of Fe@hepa (21, 32, 42, 53 µg/mL) were
tested and the results are reported in Figure 4. The cytotoxicity of Fe@hepa is always higher than that of
the other samples, but the cellular viability never dropped below 74%. Unloaded SALNs show a higher
cell viability with respect to the control, while SALNs–Fe@hepa5 show a cell viability intermediate
between the other two samples. However, significant differences are evident only within unloaded
SALNs and the other two samples at the concentration of 2 mg/mL after 2 and 4 h of treatment.
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Figure 4. Analyses of cytotoxicity of the samples at different concentrations on CaCo-2 cells (colon
rectal adenocarcinoma cell line of human origin) after 2 (a), 4 (b) and 6 h (c) of treatment, using methyl
thiazole tetrazolium test (MTT) assay. SALN concentrations of 0.8, 1.2, 1.6, 2 mg/mL correspond to
21, 32, 42, 53 µg/mL of naked Fe@hepa, respectively. Comparison between samples was performed
by ANOVA one-way test. Statistical significance levels were defined as: * (p < 0.05), *** (p < 0.001).
Error bars indicate SD; where not visible, error bars did not exceed symbol size.
2.7. Quantification of SALNs–Fe@hepa in the CaCo-2 Cell Line
Considering the results obtained from the study of cytotoxicity, the concentration of SALNs
equal to 2 mg/mL (corresponding to 53 µg/mL of Fe@hepa) is considered optimal to study the
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internalisation of the systems in the CaCo-2 cell line, a colorectal cell line adopted as a model for
lymphatic absorption [10,25].
Cells were preventively incubated for 2, 4 and 6 h with naked Fe@hepa and SALNs–Fe@hepa5,
washed with phosphate buffer saline (PBS) and then lysated.
The percentages of iron oxide found in the cell lysate respect to the amount used for the incubation
are shown in Figure 5. After two hours of incubation, the percentage of iron oxide present into cell
lysate was the same for both the samples (naked Fe@hepa and SALNs–Fe@hepa5). For the other
incubation times, iron oxide in cell lysate resulted higher after the treatment with naked Fe@hepa.
Moreover, a time-dependent correlation can be noticed: the amount of iron oxide increases with the
increasing incubation time. Significant differences can be observed between the samples after 4 and 6
h of incubation (p < 0.05).
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In order to visualise the internalisation of the sample in the CaCo-2 cell model (Figure 6), confocal
laser scanning microscopy analysis was performed. Cellular nuclei were stained in blue, SALNs were
labelled in red, while Fe@hepa, owing to their density, were visible as black spots in white-light channel.
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CaCo-2 cells were treated with Nile red-labelled unloaded SALNs, Nile red-labelled
SALNs–Fe@hepa5 and naked Fe@hepa. Figure 7A shows CaCo-2 cells incubated with Fe@hepa.
Black spots with different sizes, attributed to clusters of iron oxide nanoparticles, are visible near the
cytoplasm but clearly in a different z-thickness compared to the nuclei.
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incubati with Nile red-labell d unloade SALNs (Figure 7B), red fluorescence is noticeable
around the nuclei of CaCo-2 cells. Red spots are attributable to Nile red-labelled SALNs because no
red fluorescence is observed in untreated CaCo-2 cells (Figure 6). The image clearly indic tes that
SALNs are localised inside the cells because the red fluorescence is located in the area surrounding the
nuclei correspondent to the cytoplasm.
After treatment with Nile red-labelled SALNs-Fe@hepa5 (Figure 8), in addition to red spots, it
is possible to appreciate, in a white-light channel, a grey shading around the nuclei where also red
fluorescence is located. Moreover, black spots attributable to Fe@hepa clusters are clearly visible
externally to cells revealing the presence of non-encapsulated Fe@hepa, which have tendency to form
clusters outside the cells.
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3. Discussion
Iron oxide nanoparticles have attracted considerable interest due to their superparamagnetic
properties and their potential biomedical applications. The dimensions of these nanoparticles make
them ideal candidates for nano-engineering of surfaces to develop non-toxic and biocompatible
nanoparticles. Moreover, different coating materials can prevent their irreversible aggregation in
aqueous or biological media [26]. Vismara et al. proposed heparin coating as an attractive strategy
to achieve a theranostic aim exploiting anti-angiogenic activity of native heparin [20]. However, this
coating is instable in physiological conditions. The goal of this work was to stabilise Fe@hepa by
encapsulation in SALNs, envisaging an oral absorption through a lymphatic route.
SALNs are biocompatible, biodegradable, and can be used as controlled drug delivery and
targeting system. Owing to their composition, SALNs possess a structure very similar to that of
glyceride-rich chylomicrons which are believed to allow lymphatic transport of drugs into the intestinal
lymphatic circulation [27].
It is known that lipid nanoparticles based on triglycerides with a high carbon chain length
are less susceptible to intestinal lipase than those composed of a shorter carbon chain and are
preferably transported into the intestinal lymphatic system [11,25,28]. For this reason, Geleol™ and
Gelucire 50/13® high carbon chain length lipids, both generally recognised as safe and biocompatible
materials (manufacturer’s information), were selected as the lipid matrix for the SALN preparation.
Moreover, these lipids have a low melting point, avoiding the risk of degradation of the drug during
the preparation. Gelucire 50/13® is composed of mono-, di-, and triglycerides with mono- and
di-fatty acid esters of polyethylene glycol (PEG). Owing to the composition, it exhibits surfactant and
solubility enhancing properties that can be exploited to better incorporate lipophilic compounds and
to stabilise the lipid nanosystem [29,30]. Moreover, it has been demonstrated that Gelucire® decreases
P-glycoprotein efflux, making it a good candidate to gain lymphatic uptake [31,32].
After different formulation attempts, the preparation was optimised to achieve a reproducible
and stable colloidal suspension without an observed particle dimensional change when Fe@hepa
were encapsulated in the lipid matrix. The average diameter (around 180 nm) and the lipid nature
of the particles make this system potentially suitable for intestinal lymphatic uptake associated with
chylomicrons synthesised within enterocytes [1,6]. Alternatively, large molecular weight drug-carrier
constructs may be selectively taken up intact via the lymphatic system because their large size favours
uptake via the leakier structure of the lymphatic vessels, as compared to blood capillaries [33]. The size
of the particles suitable for this pathway is a controversial matter [34]. However, it is recognised that
the minute size of this formulation enables efficient uptake into the intestine, particularly via the
lymphatic route, favoured by particles between 20 and 500 nm in diameter [9].
Regarding the zeta potential, unloaded SALNs measured slightly negative (−16 mV), and became
progressively more negative with increasing amounts of Fe@hepa. Considering that Fe@hepa are
strongly negative (about −61 mV) due to the presence of heparin coating, the more negative surface
charge observed for SALNs–Fe@hepa with respect to unloaded SALNs can be attributable to a portion
of Fe@hepa next to the SALN surface as observed in the STEM pictures (Figure 1C,D).
Morphological studies were performed to better understand the nanoparticle structure.
The images obtained by SEM modality on the dried samples confirmed that the structure of the system
is solid due to the lipid core made of solid components (Gelucire 50/13® and Geleol™), as can be seen
in Figure 1A. However, the SEM modality does not allow the observation of particle contour due to the
poor resolution under low-voltage operating conditions (5 kV). Thus, pictures of SALNs in suspension
were obtained in STEM modality, highlighting a rough surface structure probably due to the presence
of a mixture of the two lipids in the particle matrix. In Figure 1D, at high magnification, it is possible to
observe black spots, attributable to Fe@hepa. The clusters of Fe@hepa appear surrounded by the lipid
matrix and the presence of Fe@hepa nanoparticles located in a peripheral position in the SALNs are
also visible (Figure 1C,D). The presence of Fe@hepa close to the surface of the particles might explain
the negative Z-potential value noticed for SALNs–Fe@hepa5. In addition, this finding is in agreement
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with EDX analysis that shows the superficial elemental composition of the particles. Indeed, EDX
study shows the clear presence of iron in the spectrum of SALNs-Fe@hepa (Figure 2A) while no iron
signal is evident in the spectrum of unloaded SALNs. On the other hand, the incorporation of Fe@hepa
into the lipid matrix, as observed by electronic microscopy, should lead to a stabilisation of the heparin
coating. To confirm if this goal was achieved, the release of heparin from the system in physiologic
solution was evaluated comparing naked Fe@hepa and SALNs–Fe@hepa. The results (Table 3) show
that no heparin was released from the SALNs–Fe@hepa sample, indicating that the encapsulation of
Fe@hepa inside SALNs is a good strategy to avoid the loss of heparin coating occurring for the naked
Fe@hepa. Indeed, heparin, selected as an iron oxide coating for its antiangiogenic features in tumour
environments [21–23], is linked to the particle surface by ionic bonds between the positive iron oxide
core and its negative chain. Therefore, Fe@hepa are destabilised in biological isotonic fluid where the
electrostatic interaction between iron oxide and heparin become weaker. On the other hand, when
Fe@hepa are surrounded by lipid matrix, the interaction with the biological fluids is avoided and no
leakage of heparin occurs.
To better understand the potential of Fe@hepa–loaded SALNs, the particles were prepared using
two different dosages (1 or 5 mg). The analyses indicate that in both SALNs–Fe@hepa samples the
percentage of Fe@hepa incorporated is around 90%. This means that, increasing the initial loading,
the encapsulation efficiency remains stable, suggesting that using only 1 mg of Fe@hepa the loading
capacity of the lipid system was far from saturation. As evidence of this, increasing the initial amount
of drug by five-fold, the loading increases proportionally from 5.14 µg/mg to 26.4 µg/mg (Table 2).
However, during storage it was possible to notice a progressive sediment of Fe@hepa, indicating
a probable desorption of Fe@hepa nanoparticles from the system. For this reason, the stability of
SALNs–Fe@hepa samples was monitored for one month after the preparation (Figure 3). The data
indicated that during one month, the higher loaded sample (SALNs–Fe@hepa5) was by far more
stable than the less loaded sample (SALNs–Fe@hepa1). It can be assumed that in both the cases, the
initial rapid loss of cargo is probably due to Fe@hepa non-embedded inside the lipid matrix or highly
dispersed in the suspension. Afterwards, a release of Fe@hepa with a slower rate was observed; this
was attributed to a leakage of Fe@hepa owing to its high density and to the magnetic forces between
iron oxide nanoparticles. The results indicate clearly that the loss of Fe@hepa was larger for the lower
loaded sample (SALNs–Fe@hepa1). To explain this finding, it can be assumed that when high amounts
of Fe@hepa are embedded in the lipid matrix, the forces of attraction within Fe@hepa clusters are
prevalent, stabilising the cargo. On the contrary, when poor amounts of Fe@hepa are loaded, the
forces of attraction of the clusters inside the particles are weaker in respect to the attraction of the
non-embedded particles, leading to a progressive leakage of the cargo. For this reason, all subsequent
studies on cells were conducted using only the most loaded and stable sample (SALNs–Fe@hepa5).
The MTT assay on CaCo-2 cells was performed after different times of exposure (2, 4, 6 h)
to compare the cytotoxicity induced by unloaded SALNs, naked Fe@hepa, and SALNs–Fe@hepa5.
The CaCo-2 cell line was used because it has been reported to be an indirect indication of intestinal
lymphatic transport [10,25]. The results of the analyses indicated that the lipids used to develop
SALNs are not toxic but, on the contrary, they seem to improve the cell viability as the percentage of
cell vitality observed after the treatment with unloaded SALNs resulted equal to or higher than the
control (Figure 4). Only a slight cytotoxicity was observed for naked Fe@hepa since cell viability, at the
experimental conditions adopted, never dropped below 74% compared to the control. Cytotoxicity
studies reported in the literature and conducted on naked iron oxide nanoparticles demonstrated
that these systems induce a reduction of cell viability depending on their coating, time of exposure,
concentrations and cell type evaluated [35–37]. Thus, the results obtained in this work demonstrated
that the coating with heparin allows biocompatible and non-toxic nanoparticles to be obtained. The
cytotoxicity of SALNs–Fe@hepa falls in the middle between that of unloaded SALNs and Fe@hepa
at all concentrations and incubation times considered, probably because the partial negative effects
of Fe@hepa are compensated by the positive effect of unloaded SALNs. Therefore, it is possible to
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conclude that all the samples, at all the concentrations tested, do not exhibit toxicity on CaCo-2 cell
model and the results indicate that the cytotoxicity is neither time- nor concentration-dependent.
For this reason, to carry out the studies regarding the ability of the particles to enter the CaCo2
cells, the highest concentration (cell viability more than 80%) has been selected and therefore all the
experiments were conducted using the concentration of 2 mg/mL.
The ability of the particles to enter in CaCo-2 cells was evaluated by measuring the amount of iron
transported in the cells by the two systems (Fe@hepa and SALNs-Fe@hepa5). The results (Figure 5)
indicated that the amount of iron found in the cells was higher for the cells incubated with naked
Fe@hepa respect to cells incubated with SALNs–Fe@hepa, especially for longer incubation times.
These findings seem to be in contrary to expectations because in the literature SALNs resulted able
to improve the internalisation of drugs thanks to their composition [4–6]. However, it is important
to notice that the higher percentage of iron found in the cells treated with Fe@hepa might be due to
the precipitation of naked iron oxide on the bottom of the wells, because of the loss of the heparin
coating in biological fluids. Indeed, during the experiments, it was observed that in the case of cells
treated with naked Fe@hepa, dark spots attributable to iron remained attached to the well bottom,
even after the washing with PBS (see Section 4.11). On the contrary, in the case of cells incubated
with SALNs–Fe@hepa5, the non-internalised particles were easily removed with washing owing to
the low density of their lipid composition. As a result, in the case of cells treated with Fe@hepa an
overestimation of Fe@hepa associated with the cells might have occurred.
In order to support this assumption, confocal laser scanning microscopy analysis was performed
using Nile red as a probe to visualise SALNs in the red channel, while no probe was used for Fe@hepa
since their clusters appeared as dark spots by observation in white-light channel. Observing the cells
treated with Fe@hepa, the dark spots attributed to the Fe@hepa clusters seem to be localised in a
different z-thickness compared to nuclei, indicating that they were not internalised by CaCo-2 cells
(Figure 7A). This observation indicated that iron clusters had not entered the cells, giving evidence of
the overestimation of Fe@hepa associated with the cells. On the contrary, both unloaded SALNs and
SALNs–Fe@hepa5 seem to be internalised in the cells because a slight red fluorescence is noticeable
around the nuclei, highlighting that the particles were localised in the cytoplasm. However, the iron
particles embedded in the SALNs were not visible, probably owing to their small dimension even
thought they could be considered responsible of the grey shading visible around the nuclei (Figure 8).
On the other hand, regarding the black spots visible outside the cells in the image of cells incubated
with SALNs–Fe@hepa, they could be attributable to Fe@hepa not embedded in the lipid matrix but
only absorbed on the surface or highly dispersed in the suspension according to what was observed in
the in vitro stability studies (Figure 7).
4. Materials and Methods
4.1. Chemicals
Geleol™ (Glycerol Monostearate 40–55, type I) and Gelucire 50/13® Pellets (Stearoyl Macrogol-32
Glycerides) were a kind gift from Gattefossè (Saint-Priest, France). Fe@hepa (containing 9% w/w
of heparin) were provided by the laboratory of Prof. E. Vismara and synthesised as previously
described [20]. Azure II and Nile red were purchased from Sigma-Aldrich Italia (Milan, Italy).
Potassium thiocyanate was purchased from Carlo Erba Reagenti (Milan, Italy). Hoechst 33342 stain
was purchased from ThermoFisher (Monza, Italy). Dulbecco’s Modified Eagle’s Medium with high
glucose (DMEM), L-glutamine, fetal bovine serum (FBS), penicillin–streptomycin (P/S), phosphate
buffer saline (PBS), sodium pyruvate and other culture reagents were purchased from EuroClone
(Milan, Italy).
A MilliQ water system (Millipore; Bedford, MA, USA) provided high purity water (18.2 MΩ) for
these experiments.
All other chemical reagents were obtained commercially as reagent-grade products.
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4.2. SALN Formulation
SALNs were obtained by a self-assembling process using an original technique in which no
organic solvents were employed (Figure 9). Briefly, a mixture of Geleol:Gelucire 1:1 w/w was melted
at 65 ◦C after the addition of 50 µL of MilliQ water containing Fe@hepa (1 or 5 mg) and emulsified
by ultrasound energy (Vibra-Cell, Sonic & Materials, Inc. 53 Church Hill Road, Newton, CT, USA) at
10 output Watt for 30 s. This water/oil (W/O) dispersion was rapidly solidified in ice bath and then
added to 15 mL of MilliQ water, previously heated at 65 ◦C. To obtain the SALNs, the dispersion was
homogenized for 3 min at 24,000 rpm by Ultra Turrax (T-25 basic IkaLabortecnik, Staufen, Germany)
and then cooled in ice for about 10 min to allow the SALN solidification. SALNs–Fe@hepa were purified
by centrifugation at 2000 rpm for 5 min at 20 ◦C (Rotina 380R, Hettich, Kirchlengern, Germany) to
remove the non-encapsulated Fe@hepa. The purified suspensions of SALNs were stored at +4 ◦C.
Unloaded SALNs were obtained omitting the addition of Fe@hepa in the 50 µL of MilliQ water,
while labelled SALNs for cell internalisation studies were obtained by adding Nile red (0.01%) in the
melted Geleol™.
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4.3. SALN Characterisation
SALN size and polydispersity index (PDI) were determined by photon correlation spectroscopy
(PCS) technique using a Zetasizer Nano ZS analyser system (Zetasizer version 6.12; Malvern
Instruments, Worcs, UK). The results were expressed as the average of three different measurements.
Particle surface charge (Z-Potential value) was measured by using the same apparatus, equipped
with a 4 mW He–Ne laser (633 nm) and DTS software (Version 5.0, Malvern Instruments, Worcs, UK).
Measurements were performed in triplicate and each measurement was averaged over at least 12 runs.
4.4. Morphological Studies
SALN morphological features were analysed by field-emission gun scanning electron microscopy
(SE -FEG, Nova 11 NanoSEM 450, Fei, Eindhoven, The Netherlands) using both the SEM and the
TEM mode. For the SEM mode, a few drops of the SALNs suspension were placed on an aluminum
stub (TAAB Laboratories Equipment Ltd., Aldermaston, Berks, UK) covered by a double side sticky
tab (TAAB Laboratories Equipment Ltd., Aldermaston, Berks, UK) and, after drying, vacuum coated
with gold–palladium in an argon atmosphere for 60 s (Sputter Coater Emitech K550, Emitech LTD,
Ashford, Kent, UK).
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For the TEM mode a STEM detector characterised by a low voltage electron beam (30 kV) was
employed. TEM 200 mesh Formvar/Carbor Coppergrids (TAAB Laboratories Equipment Ltd., Berks,
UK) were immersed in SALNs diluted suspension (1:10 v/v in water) and dried at room conditions
(25 ◦C, 760 mmHg) before the analysis.
Elemental composition of Fe@hepa loaded or unloaded SALNs was determined by energy
disperse X-ray (EDX) analysis with X-EDS Bruker QUANTAX-200 (Bruker Nano GmbH, Berlin,
Germany) coupled with SEM-FEG. Elements can be identified qualitatively and semi-quantitatively as
a function of the X-ray energy emitted by their electrons transferring from a higher energy shell to
a lower energy one. The X-ray emissions from the Kα or Lα levels were measured for the following
atoms: oxygen (Kα = 0.525 keV), carbon (Kα = 0.277 keV), silicon (Kα = 1.740 keV), aluminium
(Kα = 1.487 keV) and iron (Kα = 6.404 keV, Lα = 0.705 keV).
4.5. Drug Loading and Encapsulation Efficiency
The determination of Fe@hepa loaded in SALNs was performed by indirect method analysing
the amount of non-encapsulated Fe@hepa by a spectrophotometric method based on the formation of
highly-coloured complexes iron-thiocyanate ion.
Briefly, after obtaining SALNs, the separation of the non-encapsulated Fe@hepa (free Fe@hepa)
was carried out by centrifugation (see Section 4.2). The pellet was re-suspended in 200 µL of milliQ
water and digested in 1 mL of HCl 37% w/w for 2 h at 60 ◦C. Subsequently, 1.5 mL of 0.1 M solution
of potassium thiocyanate (KSCN) was added to form the red-coloured [FeKSCN]2+ iron complex.
The amount of free Fe@hepa was determined by recording absorbance at 480 nm (Lambda 35 UV/VIS,
Perkin-Elmer, Norwalk, CT, USA). The standard calibration curve for iron complex was performed
under identical conditions with known amounts of naked Fe@hepa and using KSCN and HCl solution
as blank [38].
The encapsulation efficiency (EE%) and drug loading (DL µg/mg) were calculated by using the
following equations:
EE% =










total mass of SALNs composition(mg)(lipids and Fe@hepa)
where encapsulated Fe@hepa were calculated by subtracting the amount of free Fe@hepa determined
from the initial amount added to the preparation. The experiments were conducted in triplicate and
the results were expressed as average ± standard deviation (SD).
4.6. In Vitro SALNs-Fe@hepa Stability
In order to evaluate the in vitro stability of SALNs–Fe@hepa, the amount of Fe@hepa separated
gradually at 4 ◦C for one month by spontaneous precipitation was quantified.
Practically at predetermined intervals (2, 4, 6, 8, 10, 20 and 30 days), the pellet deposited at the
bottom of the vials of the SALNs-Fe@hepa suspension was determined. The pellet was recovered,
re-suspended in 200 µL of milliQ water and digested in 1 mL of HCl 37% w/w for 2 h at 60 ◦C.
After that, the solution was analysed to determine the amount of iron in accordance with the method
described above. The analyses were performed in triplicate.
4.7. Stability of Heparin Coating
In order to analyse the stability of the heparin coating in Fe@hepa before and after the formation of
SALNs, the amount of heparin released in saline solution from naked Fe@hepa and SALNs–Fe@hepa
was evaluated.
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Briefly, a known amount of sample was incubated under magnetic stirring in 0.9% NaCl water
solution at 37 ◦C for 1 h. Then, the suspension was centrifuged for 25 min at 9500 rpm at room
temperature (Rotina 380R) in order to separate nanoparticles (naked Fe@hepa or SALNs–Fe@hepa)
from the supernatant. The amount of heparin released in the supernatant was determined by using
a modified Azure II colorimetric method [39]. Typically, aliquots (500 µL) of aqueous solution were
reacted with 4.5 mL of the Azure solution (0.01 mg/mL) and assayed at 654 nm by vis-spectroscopy
(Lambda 35 UV/VIS). Quantification was achieved by comparing the absorbance of the samples to a
regression curve determined from medium spiked with increasing amount of heparin. The experiments
were conducted in triplicate.
4.8. In Vitro Nile Red Release
Nile red released from SALNs was evaluated during 24 h. Labelled SALNs (40 mg) were incubated
at 37 ◦C in 40 mL of phosphate buffer (20 mM, pH 7.4) or DMEM added with serum, under magnetic
stirring. One millilitre of SALNs suspension was withdrawn from the system at time intervals of 30 min
and replaced with 1 ml of fresh solvent to maintain constant volume. The sample was centrifuged at
9500 rpm for 25 min and Nile red content was determined in the supernatant by vis-spectroscopy at
525 nm. The analysis was performed in triplicate.
4.9. Cell Culture
CaCo-2 cell line were cultured as a monolayer in Dulbecco’s Modified Eagle’s Medium with
high glucose (DMEM) containing L-glutamine 2 mM, penicillin 100 UI/mL, streptomycin 100 µg/mL,
sodium pyruvate and 10% of fetal bovine serum (FBS) at 37 ◦C in a humidified atmosphere (5% CO2).
Cells were sub-cultured when the confluence was ≥80%.
4.10. Cytotoxicity Assay
CaCo-2 cells were seeded at a density of 60,000 cells/well in 24-well plate in complete DMEM
medium for 48 h. Cells were then treated with Fe@hepa, unloaded SALNs and SALNs–Fe@hepa
samples at different concentrations (0.8, 1.2, 1.6 and 2 mg/mL for SALNs, and respective Fe@hepa
concentrations) for 2, 4, and 6 h.
After incubation times the methyl thiazole tetrazolium test (MTT) was performed to assess cell
viability. Optical densities were measured spectrophotometrically at 570 nm with a multiplate reader
(TecanGenios Pro with Magellan 6 software). Cell viability was expressed as a percentage of cell
survival respect to the control (untreated cells).
The experiment was performed in triplicate.
4.11. Quantification of SALNs–Fe@hepa on CaCo-2 Cell Model
The amount of Fe@hepa up-taken by the CaCo-2 cells after treatment with Fe@hepa and
SALNs–Fe@hepa at different incubation times was quantified by adapting a method previously
reported [40]. Cells were seeded in 6-well plate at density of 250,000 cells per well in complete DMEM
medium for 48 h. Then, cells were incubated with 2 mg/mL of SALNs–Fe@hepa and a proportional
amount of naked Fe@hepa (53 µg/mL) for 2, 4 and 6 h. At the end of the incubation time, cells were
washed with PBS and the amount of iron associated to the cells was quantified using the method
described in Section 4.5. The experiments were performed in triplicate. In order to compensate the
matrix effect, the calibration curve for iron quantification was prepared incubating different known
amounts of Fe@hepa in the presence of unloaded SALNs into CaCo-2 cells.
4.12. CLSM Studies of Monolayers
The confocal laser scanning microscopy (CLSM) of fixed cells was performed with a Leica DM
IRE2 microscope (Mannheim, Germany) and a Leica Confocal System equipped with a scanner
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multiband 3-channel Leica TCS SP2 with AOBS, laser diode blue COH (405 nm/25 mW), laser Ar
(458 nm/5 mW) (476 nm/5 mW) (488 nm/20 mW) (496 nm/5 mW) (514 nm/20 mW), laser HeNe
(543 nm/1.2 mW), laser HeNe (594 nm) (orange) and laser HeNe (633 nm/102 mW). CaCo-2 cells,
seeded at a density of 100,000 cells per well in a chambered coverglass (Lab-Tek®, Thermo-scientific,
Milan, Italy), were incubated with naked Fe@hepa (53 µg/mL), Nile red-labelled unloaded SALNs
(2 mg/mL), and Nile red-labelled SALN–Fe@hepa (2 mg/mL). After 4 h of incubation, the treated cells
were washed twice with PBS, fixed in paraformaldehyde (3% w/v) for 20 min at room temperature,
stained with 2 µg/mL Hoechst 33342 dye and analysed with CLSM.
4.13. Statistical Analysis
Statistical analysis was performed using the one-way analysis of variance (ANOVA). The data are
represented as mean ± SD. Difference was considered statistically significant at p-values less than 0.05.
5. Conclusions
In this work it was demonstrated that SALNs are an efficient carrier for Fe@hepa, reducing
their cytoxicity to CaCo-2 cells and overcoming the loss of heparin coating in biological fluids.
SALNs–Fe@hepa resulted able to be efficiently internalised in CaCo-2 cells, and were demonstrated
to be a promising tool for delivering the theranostic Fe@hepa to lymphatic circulation by the oral
route, although further studies are needed to comprehend the potential in vivo applications. Moreover,
it would be interesting in the future to replace native heparin with low-molecular-weight heparins,
which showed a less anticoagulant activity while maintaining antiangiogenic activity, in order to
reduce risks of bleeding.
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